Life Science-Medical Devices

As the world`s third largest economy with a rapidly aging population, Japan presents a tremendous growth opportunity for Life Sciences companies.

Life-Science-Pharma

As the world`s third largest economy with a rapidly aging population, Japan presents a tremendous growth opportunity for Life Sciences companies.

Industrial

The work of the Industrial Practice Group encompasses industries such as transportation, electronics, materials, energy, semiconductor and manufacturing. Each market segment requires specialized talent for roles in engineering, sales, and leadership.

Technology

The Information Technology Industry is one of the most important industries and is the key driver of the world economy. It has evolved in meeting the ever changing landscape of the world. In this time of Digital Transformation, we understand the needed balance on both client side and candidate side. People are key assets.

Global Markets

Despite the recent years of financial turmoil, financial institutions continue to focus on niche products and services in the Asia-Pacific region. Our Financial Services Practice is specialized in servicing the fixed income sector, which has allowed Ingenium to develop in-depth market knowledge and a strong candidate network – the key factors for success.

Recent Blog posts

Join EyeForPharma Japan, May 17-18, Tokyo, Japan

eyeforpharma Japan 2017 is your chance to take charge of your commercial excellence and explore ways to remodel strategies to ensure success in the changing environment. It is a premier opportunity to get insights from medical experts and key leaders in Pharma. Top speakers: Click for eyeforpharma Japan’s Full Speaker Faculty Order 2017 brochure Why attend

Continue Reading

Competing with the Chinese Factory of 2017

BY Nanette Byrnes – Senior Editor, Business Reports at MIT Technology Review Deep manufacturing expertise and extensive supply chains give China a lead that will be tough to overcome. During his presidential campaign and since moving to the Oval Office, Donald Trump has spoken a lot about manufacturing in the U.S. and its competition with

Continue Reading

Designing Effective Incentive Plans for Rare Disease Teams

BY Michael Thomas – ZS.com While the pharmaceutical industry is still just skimming the surface when it comes to developing therapies to address the 7,000-plus known rare diseases, drug development is only half of the battle. Organizations that have successfully gained approval for their therapies in the U.S. and abroad face significant challenges when planning

Continue Reading